Contribute Try STAT+ Today

Earlier this week, the U.S. government awarded a $354 million contract to a new public benefit company called Phlow to make generics that are in short supply during the pandemic. The move, which is designed to lessen U.S. reliance on foreign suppliers, prompted questions, including some about Phlow chief executive Eric Edwards, who co-founded Kaleo, a company that was scolded by a Senate subcommittee for price gouging on an opioid overdose antidote. Moreover, Phlow has not made any products, although Edwards tapped experienced pharmaceutical executives for his management team and board. Among them is the head of Civica Rx, a nonprofit that emerged in response to shortages and has created a network of companies supplying hospitals with generics. We spoke with Edwards about his reaction to the skepticism and his plans for Phlow and and its role in creating a national strategic reserve for active pharmaceutical ingredients. This conversation has been lightly edited. 

Before we talk about Phlow, you have concerns about perceptions that you were involved in raising prices while at Kaleo. You and your brother founded the company. You were still a founder and owner while those pricing decisions were made. You were happy to accept the praise and publicity for the good things the company was doing, such as (product) donations… It sounds like you want it both ways. I’d like to hear your response to what you say is unfair.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy